To establish an accurate molecular model of human branched-chain amino acid (BCAA) metabolism, the distribution, activity, and expression of the first 2 enzymes in the catabolic pathway-branched-chain-amino-acid aminotransferase (BCAT) and branched-chain ␣-keto acid dehydrogenase (BCKD) complex-were determined in human tissues. The same enzyme activities were measured in rat and African green monkey tissues. Overall, the activities of BCAT and BCKD were higher in rat than in human and monkey tissues; nevertheless, the ratio of the 2 activities was similar in most tissues in the 3 species. Total oxidative capacity was concentrated in skeletal muscle and liver (>70%) with muscle having a higher proportion of the total in humans and monkeys. In humans, brain (10-20%) and kidney (8-13%) may contribute significantly to whole-body BCAA metabolism. Furthermore, in primates the high ratio of transaminase to oxidative capacity in the entire gastrointestinal tract serves to prevent loss of essential BCAA carbon and raises the possibility that the gastrointestinal tract contributes to the plasma branched-chain ␣-keto acid pool. Quantitative polymerase chain reaction was used to examine expression of human branched-chain ␣-keto acid dehydrogenase kinase (BCKDK), the key enzyme that regulates the activity state of the human BCKD complex and human BCAT isoenzymes. To design the primers for the polymerase chain reaction, human BCKDK was cloned. BCKDK message was found in all human tissues tested, with the highest amount in human muscle. As in rats, there was ubiquitous expression of mitochondrial BCAT, whereas mRNA for the cytosolic enzyme was at or below the limit of detection outside the brain. Finally, the role of BCAA in body nitrogen metabolism is discussed.
INTRODUCTION
Human protein metabolism is a dynamic process in which protein synthesis and breakdown occur simultaneously in a process termed protein turnover. The essential branched-chain amino acid (BCAA) leucine has become the most widely used tracer for studying protein metabolism in humans (1) . Wholebody protein turnover and oxidation can be estimated by using leucine tracers in a single experiment. Although increasingly more complex kinetic models have been developed to estimate human leucine and protein metabolism, the accuracy of these models is still controversial (2) . Regardless of the model, a clear understanding of human BCAA metabolism is required both in nutritional and clinical studies.
The first step in catabolism of BCAAs (leucine, isoleucine, and valine) is reversible transamination to form their respective ␣-keto acids: ␣-ketoisocaproate, ␣-keto-␤-methylvalerate, and ␣-ketoisovalerate. This reaction is catalyzed by branched-chainamino-acid aminotransferase (BCAT). Our laboratory has established that there are 2 mammalian BCATs: a mitochondrial (BCATm) and a cytosolic (BCATc) isoenzyme (3) (4) (5) (6) . The second step in BCAA catabolism is irreversible oxidative decarboxylation of the branched-chain ␣-keto acids catalyzed by the mitochondrial branched-chain ␣-keto acid dehydrogenase (BCKD) complex. This step commits the BCAA carbon skeleton to the degradative pathway. The mammalian BCKD complex contains multiple copies of 3 enzymes (7): branched-chain ␣-keto acid decarboxylase (E1); dihydrolipoamide acyltransferase (E2), and dihydrolipoamide dehydrogenase (E3; EC 1.8.1.4). The activity of the complex within a tissue is regulated by phosphorylation and dephosphorylation catalyzed by a specific kinase (BCKDK) and phosphatase (7, 8) . Information about the tissue-specific expression of BCKD in humans is limited. Furthermore, because the complementary DNA (cDNA) sequence for human BCKDK has not been reported, the pattern of expression of this key regulatory enzyme is also not known.
The current hypothesis that oxidation of BCAA involves extensive movement of metabolites between muscle and liver is based on observed tissue-specific differences in BCAA catabolism in the rat model. These differences result from the tissue BCAT content and activity state of BCKD (9, 10) . The BCAT isoenzyme location also dictates the compartmentalization of intracellular BCAA pools for anabolism and catabolism. In rats, BCATm is found in most tissues whereas BCATc is restricted to the brain, ovary, and placenta (6) . Neither BCAT isoenzyme is found in the liver (5, 6) . Conversely, the activity state of BCKD complex is high in the liver, low in skeletal muscle, and intermediate in the kidney and heart (11, 12) . Although there is some information about the activity of BCAT and BCKD in human tissues (13) (14) (15) (16) , no systematic study using molecular probes has been reported.
In this study the activity and expression of BCAT isoenzymes and BCKD were determined in representative samples of rat, human, and nonhuman primate (African green monkey) tissues. The nucleotide sequence and deduced amino acid sequence for human BCKDK as well as the tissue-specific expression of this key enzyme are presented.
MATERIALS AND METHODS

Rat tissues
Male Sprague-Dawley rats (n = 5) weighing 250-300 g were used. The rats were anesthetized with sodium pentobarbital. The liver, kidney, heart, skeletal muscle (gastrocnemius), adipose tissue (epididymal), brain, small intestine (ileum), pancreas, stomach, and colon were removed and freeze-clamped immediately with aluminum tongs precooled in liquid nitrogen and stored in liquid nitrogen until analyzed. The protocol complies with the guidelines for the care and use of Laboratory Animals.
Human tissues
The experiments were approved by the Institutional Ethics Committee at the Bowman Gray School of Medicine. Samples were obtained from patients undergoing surgical procedures. In general, 100-300 mg tissue was used. All samples were obtained from tissues that would have been discarded during surgery. Heart tissue (atrial appendage) was obtained from patients undergoing cardiac bypass surgery. Brain tissues (cerebrum and hippocampus) were acquired from patients undergoing lobectomy for seizure control. Some tissue samples were taken from macroscopically normal parts that had been removed because of cancerous growth (kidney cortex and liver). Adipose tissue was subcutaneous. Muscle was obtained from patients undergoing surgery for free flap (rectus abdominus), general surgery (abdominal wall muscle), and leg amputation. Colon and intestine (ileum) were obtained from patients undergoing surgical resection. Stomach, abdominal wall muscle, and adipose tissue were also obtained from a single organ donor who had given consent for use of the tissue for research purposes. These tissues were perfused with ice-cold ViaSpan (DuPont Pharma,Wilmington, DE) before removal. The tissues were freeze-clamped immediately and stored in liquid nitrogen until analyzed. In most cases, tissues were frozen within minutes of removal. The maximum time between removal of a tissue and quick freezing was 30 min. Stability of BCAT and BCKD activities was checked initially by using samples frozen from 0 to 10 min up to a maximum of 2 h after removal. BCAT activity was stable up to 1 h and BCKD up to 30 min. The tissues were obtained from males and females aged 2 mo to 68 y.
Monkey tissues
Tissues were obtained from monkeys involved in a study on the effect of dietary cholesterol on lipoprotein metabolism (17) .
Twelve adult male African green monkeys (Cercopithecus aethipos) aged 4-5 y and weighing 3.32-5.38 kg were used. They were assigned into 3 groups (low-, moderate-, or high-cholesterol diets) of 4 monkeys per group. The diets and study protocol are described in detail elsewhere (17) . Briefly, the monkeys were fed the commercial stock Monkey Chow (Ralston Purina Co, St Louis)-a low-fat, low-cholesterol, high-fiber diet-for 7 mo. The monkeys were then fed the experimental diets for 6-7 y. The experimental diet contained, as a percentage of energy, 17% protein, 35% fat, and 48% carbohydrate with 0.014, 0.096, or 0.191 mg cholesterol/kJ in the low-, moderate-, and high-cholesterol diets, respectively (17) . At the end of the experiment the animals were anesthetized, perfused with ice-cold physiologic saline (17) , and killed. The liver, kidney cortex, skeletal muscle (bicep), small intestine (ileum), pancreas, subcutaneous adipose tissue, and stomach were removed and freeze-clamped immediately. The skull was then opened and brain tissue (cerebrum and cortex) was removed. Brain tissue was also obtained from 2 other monkeys that had consumed only the commercial stock diet. Tissues were stored in liquid nitrogen until used. Tissue BCAT and BCKD activities from each group of 4 animals were analyzed by using analysis of variance (ANOVA). No statistically significant differences were found between groups; therefore, the data from all 3 groups were combined.
BCAT assay and tissue extraction
Procedures were developed for quantitative extraction of BCAT from tissue samples. Frozen tissue was pulverized with a mortar and pestle cooled in liquid nitrogen. Depending on the tissue, connective tissue was removed before the powder (50-100 mg) was transferred to cooled preweighed centrifuge tubes. The tissue was suspended in buffer (1 g tissue/4 mL extraction buffer) containing 25 mmol HEPES/L (pH 7.4), 0.4% CHAPS (by wt) protease inhibitors (4), 20 mmol EDTA/L, 20 mmol EGTA/L, and 5 mmol dithiothreitol/L. The tissue suspension was then subjected to 3 rounds of freeze-thaw sonication before centrifugation at 10 000 ϫ g for 30 min. The supernate was assayed for BCAT activity, which was determined as described previously by using ␣-keto [1- 14 C]isovalerate and isoleucine (3). A unit of activity was defined as 1 mol valine formed/min at 37 ЊC. The isoenzymes BCATm and BCATc were extracted quantitatively by this procedure and activity was maintained for several days if the extract was kept frozen at Ϫ80 ЊC.
Determination of BCKD activity
Extraction of the BCKD complex from tissues was performed essentially as described by Block et al (18) by using the modification described by Shimomura et al (19) with 50-100 mg tissue. BCKD activity was measured as 14 CO 2 release from ␣-keto [1- 14 C]isocaproate. Total BCKD complex activity, which is an estimate of enzyme amount, was measured after activation of a separate aliquot of the same sample in the presence of magnesium sulfate and a broad specificity phosphatase as described by Shimomura et al (19) . The phosphatase was partially purified from rat liver by using the protocol described by Harris et al (20) . The activity state of BCKD is the ratio of actual activity before activation to total activity obtained after activation by phosphatase treatment. A unit of activity was defined as 1 mol 14 CO 2 formed/min at 37 ЊC.
RNA preparation, cDNA synthesis, and polymerase chain reaction Total RNA was isolated by extraction with guanidinium isothiocyanate (21) . First-strand cDNA was synthesized using oligo(dT) primer and SuperScript II reverse transcriptase (Gibco BRL, Gaithersburg, MD). Briefly, human total RNA (1 g) and 300 ng oligo(dT) primer were denatured by heating to 70 ЊC for 10 min, chilling quickly on ice, and subsequently reverse transcribed by incubating with 10 mmol dithiothreitol/L, 1 mmol deoxynucleotide triphosphate/L, and 200 U SuperScript II reverse transcriptase for 1 h at 37 ЊC (50 L total volume) followed by enzyme denaturation at 70 ЊC for 15 min. Incubations without reverse transcriptase were used as negative controls. Polymerase chain reaction (PCR) amplification was conducted by using Taq DNA polymerase (Promega, Madison, WI). Two microliters cDNA were added to each reaction mixture (50 L) containing 20 pmol of each primer, 500 mol 1 mmol deoxynucleotide triphosphate/L, 10 mmol tris-HCl/L (pH 9.0), 50 mmol KCl/L, 1.5 mmol MgCl 2 /L, and 1 U Taq DNA polymerase. An amplification program of denaturation (94 ЊC, 1 min), annealing (60 ЊC, 2 min), and extension (74 ЊC, 1 min) was used followed by incubation at 74 ЊC for 5 min. Ten-microliter samples of each reaction mixture were analyzed on 2% agarose gel followed by staining in ethidium bromide.
Specific primers for each individual cDNA were selected by using the computer program PRIME (version 8; Genetics Computer Group, Inc, Madison, WI). Human BCATc cDNA (accession no. U21551) was amplified by using oligonucleotides with the following sequences: sense primer 5-AGC-CATATGGATTGCAGTAACGGATC-3and antisense primer 5-TCAGGATAGCACAATTGTC-3. The last 20 nucleotides of the sense primer correspond to the first 20 bases encoding the human BCATc protein and the first 6 nucleotides contain an Nde I restriction site. The antisense primer corresponds to nucleotides 1139-1158 in the reported sequence. The amplified product is 1164 base pairs (bp) and corresponds to the complete coding region of the BCATc cDNA. For human BCATm the sense primer was 5Ј-ATGGCCGCAGC-CGCTCTG-3Ј and the antisense primer was 5Ј-AGTAGA-CAAAGATGTTCATG-3Ј. The 820-bp product corresponds to nucleotides 1-820 of the coding sequence of the full-length human BCATm cDNA (22) . The specificity of BCATm and BCATc primers was checked against plasmid DNA containing the respective BCATm and BCATc cDNAs. A primer pair was chosen to amplify the human BCKD E2 subunit, which yielded a product of 234 bp (nucleotide bases 985-1219 of the cDNA coding sequence) (accession no. M19301). The sense primer sequence was 5-GGATGAAAACTGCCAGA-3 and the antisense primer sequence was 5-GGTACCAC-CAATTGATC-3. Human BCKDK cDNA was amplified with the following sense and antisense primers: 5-TATATCCGTGCCTTCC-3 and 5-ATCTTTGTGAGCGATTCC-3, respectively. The amplified product was 587 bp and corresponded to nucleotides 475-1062 in the cDNA sequence. Glyceraldehyde-3-phosphate-dehydrogenase (accession no. X02231) was amplified by using the following primers: sense primer sequence 5-CCTTCATTGACCTCAACTACATGG-3Ј and antisense primer 5Ј-TCCACCACCCTGTTGCTGTAGC-3Ј. An 870-bp (184-1054) product was obtained.
Quantification of BCKD kinase and BCATm mRNAs by competitive RT-PCR
Quantitative reverse transcriptase-PCR (RT-PCR) was performed according to the protocol provided by Clontech Laboratories, Inc (Palo Alto, CA). Specific DNA standards (mimic DNA) were prepared from neutral DNA (provided by Clontech) producing mimic DNA in which the 5Ј and 3Ј ends were compatible with the primers used to amplify sample cDNA. For mimic DNA we designed composite primers that gave products of 468 bp (internal control for BCKDK) and 630 bp (internal control for BCATm). Amplification of the mimic DNA with these primers resulted in a PCR product of different size from the target cDNA (820 bp for BCATm and 587 bp for BCKDK). RT-PCR was performed as described above. The number of cycles used for amplification of the each enzyme's specific sequence was adjusted to keep the reaction within the exponential phase. In each tissue the amount of messenger RNA (mRNA) present was determined by identifying the concentration of standard mimic cDNA at which the sample and the standard PCR bands exhibited equal intensity.
Cloning of BCKDK
A human clone with high-sequence homology to rat BCKDK (8) was found by searching the expressed sequence tag (EST) database of the National Center for Biotechnology Information (National Library of Medicine, Bethesda, MD). This EST (obtained from Genome Systems, St Louis) was sequenced by the dideoxy chain-termination method (23) by using Sequenase (version 2; US Biochemical Corp, Cleveland). The sequence was confirmed by automated sequencing by using the fluorescent dye termination method carried out by the Biochemistry Biotechnology Facility at the Indiana School of Medicine.
RESULTS
Tissue distribution of BCAT activity and of BCAT isoenzyme expression
In rats, the absence of BCAT in the liver, the concentration of body BCAT activity in extrahepatic tissues, as well as the low peripheral BCKD activity state, sets up the interorgan shuttling of BCAA metabolites. To quantify this model in humans and a nonhuman primate, the tissue distribution of BCAT activity in human and distribution of BCAT activity in African green monkey and rat tissues were compared ( Table 1) . As reported previously, BCAT activity in rats was highest in the pancreas followed by that in the stomach, heart, kidney, brain, and skeletal muscle (9, 24) ; lower levels of activity were detected in the colon, small intestine, and adipose tissue. The activity routinely measured in rat liver represents contributions from other enzymes (5) . In monkeys, BCAT activity was also highest in the pancreas followed by that in the kidney, stomach, and brain. All tissues tested had measurable activity, with the lowest activity found in adipose tissue. Human pancreas tissue was not available; however, the data of Goto et al (13) from autopsy material indicate that BCAT activity is probably highest in human pancreas. Of the human tissues examined, kidney had the highest activity followed by brain and stomach. Measurable BCAT activity was also found in tissues of the gastrointestinal tract. The distribution of BCAT activity in monkey tissues was very similar to that found in human tissues (Table 1 ). In general, the level of BCAT activity in rat tissues was anywhere from 2-to 10-fold higher than in human or monkey tissues. Notable exceptions were adipose tissue, small intestine, and liver ( Table 1 ). The results show that there is considerable potential for BCAA metabolism in tissues of the gastrointestinal tract and brain of all species.
It was shown previously by immunologic analysis that BCATm is expressed ubiquitously in rat tissues (5) and that BCATc expression is restricted to brain, ovary, and placenta (6, 9) . The availability of cDNA for both human enzymes allowed us to address the question of the tissue-specific expression of BCATm and BCATc mRNA in human tissues. Because of the low concentrations of BCAT message, it was necessary to use a highly sensitive method, RT-PCR, to detect mRNAs for the BCAT isoenzymes. As illustrated in Figure 1 , BCATm mRNA was detected in all human tissues that were examined. BCATm mRNA appeared most abundant in skeletal muscle, brain, kidney, and intestine. Quantitative PCR analysis of the BCATm mRNA concentration confirmed that human skeletal muscle had the most abundant message followed by kidney and brain whereas liver had low concentrations of BCATm message. Therefore, the pattern of expression of BCATm mRNA in human tissues was similar to that in the established rat model. Nevertheless, there did not appear to be a close correlation between measurable BCAT activity and the concentration of BCAT mRNA. BCATm message was also detectable in adipose tissue (data not shown), suggesting that this isoenzyme is responsible for the activity measured in adipose tissue. BCATc mRNA was clearly found in human brain. On the other hand, only trace amounts of transcript or none were detectable in other tissues. Because of its limited expression in tissues outside the brain (expression in ovary and placenta were not determined), we did not quantify BCATc mRNA. The data suggest that contrary to results from an early study (13) , there is likely to be little, if any, expression of BCATc isoenzyme in tissues outside the brain in humans.
BCKD activity
Irreversible oxidative decarboxylation of the products of transamination, the branched chain ␣-keto acids, by BCKD commits BCAA to the degradative pathway. Therefore, the BCKD complex activity and activity state were determined in the same rat, human, and monkey tissues as were used for determination of BCAT, and the results are summarized in Table 2 . The tissue distribution of actual BCKD activity was quite similar in human and monkey tissues, with the highest activity found in kidney followed by that in the liver, brain, and heart. Except for human liver, which had lower total activity than that found in monkey liver, total BCKD activities in human and monkey tissues were also very similar. The activity state of the complex in the tissues varied considerably between species and was definitely lower in human than in monkey or rat liver. Significant BCKD activity was found in monkey and rat pancreas. Compared with rat tissues, the actual and total activities of BCKD in human and monkey tissues were in many cases one-tenth the BCKD activities measured in rat tissues (liver, heart, adipose tissue, and stomach). When compared with other tissues, actual and total BCKD activities in the intestinal tract appeared limited, suggesting that little loss of indispensable BCAA carbon is likely to occur in these tissues in primates. Rats, surprisingly, had higher BCKD activity in the stomach than in the brain or skeletal muscle, and humans and monkeys also had BCKD activity in the stomach.
Transamination and oxidative capacities
To determine the relative contributions of the major tissues and organs to whole-body transamination, we estimated the transaminase capacity from enzyme activity by taking into account organ weight as a proportion of body weight ( Table 3) . In rats, transaminase capacity was highest in muscle followed by the gastrointestinal tract, kidney, and brain. Likewise, in humans and monkeys, skeletal muscle had the highest transamination capacity, accounting for 66% and 80% of total transaminase in humans and monkeys, respectively. Another noticeable difference in humans compared with the other 2 species was the higher percentage of BCAT found in the brain. Although absolute transamination capacities were quite different in rat and human tissues, except in the brain and liver, the contribution of each organ or tissue to whole-body activity was actually quite similar in the different species. The high BCAT activity in the rat stomach accounted for the higher proportion of transamination found in the gastrointestinal tract in rats than in that of humans and monkeys.
The distribution of BCKD (oxidative) capacity in rat, human, and monkey tissues is summarized in Table 4 . In rats, the bulk of the actual oxidative capacity is found in the liver. Together, skeletal muscle (29%) and liver (60%) account for almost 90% of body oxidative capacity (total activity) in rats. However, in humans and monkeys, skeletal muscle represented Ϸ50-60% of oxidative capacity (actual or total). Noticeable differences in the contribution of human and rat brain to body oxidative capacity are evident in Table 4 . Overall, the sum of oxidative capacity (actual and total) in human and monkey tissues was about onetenth the oxidative capacity found in rats.
Cloning and expression of human BCKDK
Control of oxidation of BCAA is determined by the activity state of BCKD, which is regulated primarily by the activity of BCKDK (8) . The expression of this key regulatory enzyme in human tissues is not known; therefore, the cDNA for human BCKDK was cloned. The nucleotide and deduced protein sequences of human BCKDK are presented in Figure 2 . The cDNA-encoding human BCKDK has 1 open reading frame defined by an ATG triplet at base 91, an in-frame stop codon at base 1327, and a poly(A) tail at the 3Ј end of a 370-nucleotide sequence extending beyond the stop codon. On the basis of sequence identity with rat BCKDK, the mature form of human BCKDK is assumed to start after a 30-amino acid mitochondrial targeting sequence (27) . If this is the case, the predicted mature protein is 382 residues in length with a calculated molecular weight of 43 288. Assignment of the first amino acid of the mature protein is provisional, however, because no direct amino acid sequencing information is available for the human protein. Alignment of the nucleotide and deduced protein sequences of rat and human BCKDK revealed 88.2% nucleotide and 95.9% amino acid identity (data not shown). The amino acid identity increases to 98.2% when mature rat and human proteins are compared. The amino acid sequences of human BCKDK within the 5 subdomains suggested to be involved in the catalytic activity of the mitochondrial protein kinase family (28) are identical to the corresponding sequences in rat BCKDK and are very similar to those of the pyruvate dehydrogenase kinase isoenzymes.
BCKDK-specific primers were designed by using the cDNA sequence, and PCR was used to examine expression of BCKDK in human tissues. In Figure 3 , the pattern of expression of BCKDK is compared with 1 of the subunits of the BCKD complex, the dihydrolipoamide acyltransferase subunit (E2). Although the pattern of expression of E2 and BCKDK messages was not identical, both transcripts were found in all tissues tested. Quantification of BCKDK message confirmed that the highest expression of kinase mRNA was in skeletal muscle ( Figure 3 ). Intermediate concentrations of BCKDK message were measured in the brain and kidney. E2 mRNA was prominent in human kidney tissue, which has a high BCKD activity. The lowest concentrations of BCKDK mRNA were found in the liver and small intestine. Qualitatively, skeletal muscle was the only tissue that appeared to have a high ratio of kinase to E2 message ( Figure 3 ).
DISCUSSION
Model of BCAA metabolism: rat compared with primate
There were several striking features of the model of BCAA metabolism originally developed with use of the rat. The high ratio of transaminase to oxidative capacity in skeletal muscle, absence of BCAT, and high oxidative capacity in the liver led to the prediction that there is extensive interorgan cooperation in the catabolism of BCAA and their metabolites (29, 30) . The catabolic pathways of most essential amino acids are confined to the liver; hence, Harper (31) has argued that this complex regulatory system evolved not merely to conserve essential BCAAs, but because BCAAs play a critical role in body nitrogen metabolism. The results show clearly the potential for extensive oxidation and transamination of BCAA in peripheral tissues in humans and primates and suggest that there may be more limited transfer of metabolites between skeletal muscle and liver in primates than in rats.
The prevailing view in humans is that skeletal muscle is the major site of both BCAA transamination and oxidation. Tissuespecific BCAT activity and expression, BCKD activities, and BCKDK expression in the 3 species (rats, monkeys, and humans) support in vivo observations showing that skeletal muscle is a major site of BCAA metabolism in humans (32) . In agreement with 2 earlier studies that used autopsy material (13, 14) , it is also evident that BCAT and BCKD activities are much higher in rats than in humans or monkeys. On the other hand, contrary to the early observations of Goto et al (13) , observations on BCAT isoenzyme expression suggest that in humans, as in rats, BCATm is the predominant isozyme and BCATc expression is probably limited to the brain.
On examination of the tissue enzyme activities of the 3 species, enzyme distribution in rats does not appear to resemble closely that of humans and primates because there are higher activities in rat tissues. However, when enzyme activity values were used to calculate ratios of BCAT to BCKD for the different tissues (Tables 1-4) , the ratios for rat, human, and monkey tissues were similar. In skeletal muscle, for example, the ratio of BCAT to total BCKD is essentially the same in all 3 species (Ϸ25-30). In fact, for all tissues, with a few exceptions, BCAT-BCKD activity ratios in the 3 species appear similar. One exception is rat liver, which does not contain BCAT. Rat epididymal fat also has a proportionally higher total BCKD activity (ratio of 5) than do human and monkey subcutaneous fat (ratios of 52 and 27, respectively). As expected, monkeys are generally a good model for humans, with the caveat that the BCKD activity state in several tissues appears to be higher in monkeys than in humans.
Although skeletal muscle may represent the quantitatively most important site of BCAA disposal in humans, the pattern of tissue distribution of BCAT and BCKD suggests that other organs, particularly the brain and kidney, may also contribute to whole-body BCAA oxidation. The high volume of blood flow to the kidney (33) and the high transaminase and oxidative (BCKD) capacity in human and monkey kidney supports this hypothesis. Indeed, kidney transplantation might prove effective in treating patients with maple syrup urine disease. The brain, which also receives significant blood flow, was estimated to contain 20% of actual and 10% of total human BCKD capacity. It has been established that BCAAs cross the blood-brain barrier rapidly (34) , with influx of leucine exceeding that of other amino acids (35); a role for BCAA in the glutamate-glutamine shuttle has been postulated.
Significant BCAT activity but limited oxidative capacity in the entire gastrointestinal tract in primates presumably serves to prevent the loss of essential BCAA during feeding. These observations also raise the possibility that transamination can serve as a source of blood branched-chain ␣-keto acids throughout the digestive process, that the gut could serve as a retrieval system for ␣-keto acids produced by gut bacteria, or both. Williams et al (36) suggested that protein-derived amino acids in the gut are utilized by skeletal muscle during and immediately after exercise. The quantitative importance of human liver, the function of the high BCAT activity in the pancreas in all species, and the possible role for adipose tissue in obese individuals remains to be established.
BCAA oxidation
Irreversible loss of the essential BCAA carbon skeleton occurs at the BCKD step. The kinase, BCKDK, is thought to be the primary regulator of the activity state of the BCKD complex (8) . Liver, which has the highest BCKD activity state of any tissue in rats, contains the lowest amount of BCKDK protein and mRNA (liver < kidney < heart) (37). BCKDK mRNA was found in all human tissues that had BCKD activity and expressed E2 mRNA; the highest concentration was found in skeletal muscle followed by that in the brain, kidney, and heart. Human kidney 1 % of total in brackets. Data were calculated from the enzyme activities presented in Table 1 and the percentage organ weight of total body weight (g/100 g body wt) (25, 26) . BCAA, branched-chain amino acid. had the lowest observed activity state and highest total BCKD activity. Although kinase protein could not be measured, skeletal muscle was the only tissue in which the concentration of kinase message appeared higher than that of the E2 message. Several studies (32, 38, 39) have reported that infusion of BCAA or a protein meal results in increased muscle BCAA uptake. BCAA infusion has been shown to increase the BCKD activity state in skeletal muscle (40) . Our mean total muscle BCKD activity (Table 2 ) was similar to the value reported for biopsied leg muscle (quadriceps femoralis) by van Hall et al (40) (4.3 ± 1.0 mU/g wet wt). However, the activity state was lower (Ϸ5%) in their study than in ours (26%). BCKD activities as a function of muscle type and time before freezing ( Table 5) indicate that some but not all of the difference in activity state may be accounted for by the time that elapses between removal and freezing of the tissue. The observations also raise the possibility of muscle type-specific differences in BCKDK content. Effects of anesthesia, surgical stress, or both on activity state may also have contributed to the observed differences; however, this complication cannot be avoided if samples of several tissues are required. The lack of a clear difference in activity patterns between monkeys (fast removal of cooled tissue) and humans (variable time in surgery) suggests that tissue-specific variables affect these measurements. The results do suggest that actual in vivo BCKD activity may be lower than values measured in excised tissue, and that the most reliable number is total activity.
Assays of BCKD in skeletal muscle are the most problematic of all tissues because polyethylene glycol precipitation is required to concentrate the complex. To obtain a reliable estimate of total activity, it is necessary to use a specific 3% and 7% cut with polyethylene glycol or to treat the sample with phosphatase (10, 19, 41) . Indeed, estimates of actual activity in skeletal muscle are often lower than measured BCAA oxidation in situ (10, 42, 43) . For example, leucine oxidation in the rat hindquarter was Ϸ2 nmol · min Ϫ1 · g wet wt Ϫ1 (3-5 nmol with all 3 BCAAs), with total intracellular branched chain ␣-keto acid concentrations ≤ 20 mol/L. Measured actual BCKD activity (100 mol ketoisocaproate/L) from several studies ranges from ≤ 1 nmol · min Ϫ1 · g tissue Ϫ1 (10, 19, 41 ) to 3.8 nmol · min Ϫ1 · g tissue Ϫ1 in our study. Although direct extrapolation of BCKD activity in vitro to oxidation rates in vivo must be made with caution, data on BCKDK expression provide strong circumstantial evidence that phosphorylation will be a key regulator of oxidation in human muscle. Furthermore, the high expression of BCKDK in skeletal muscle raises the possibility that regulation of BCAA oxidation may occur primarily in this tissue.
Role of BCAA in body nitrogen metabolism
There has been considerable debate about the sources of the ammonia (and carbon skeleton or C-5 carbon) for glutamine synthesis and ammonia produced in skeletal muscle during exercise (44, 45) . It is now believed that the purine nucleotide cycle contributes ammonia only during high-intensity exercise (44, 45) . The extensive uptake of BCAA by skeletal muscle, the presence of BCAT, and the observation that BCAAs stimulate glutamine and alanine release from skeletal muscle (31, 32, 46) has led to the hypothesis that BCAA transamination plays a significant role in glutamine and alanine metabolism. This hypothesis is consistent with forearm and leg arteriovenous amino acid differences measured in vivo in humans (44, 45) , and studies showing increased ammonia and glutamine production with BCAA supplementation during exercise (40) . However, Wagenmakers et al (44) also observed that BCAA supplementation leads to deterioration of exercise performance, suggesting that BCAA metabolism compromises citric acid cycle activity.
Our finding that BCATm is the BCAT isoenzyme form expressed in peripheral tissues has metabolic consequences that effect the purported role of BCAA in body nitrogen metabolism. If transamination occurs in the mitochondria, mitochondrial ␣-ketoglutarate is used to form glutamate. Because of the reversibility of transamination reactions, BCAA ␣-amino nitrogen will rapidly label the tissue free amino acid pool. However, net transfer of nitrogen from BCAA into the muscle pool requires that the carbon skeleton, ie, the branched-chain ␣-keto acid, is either released from the tissue or is oxidized. Although the ratio of ␣-keto acid release to ␣-keto acid oxidation does have an effect on the question of the interorgan cycling of metabolites and the source of the plasma ␣-keto acid pool, only actual loss of the BCAA carbon skeleton from the muscle pool, not the pathway, really effects the net flux of BCAA nitrogen into the tissue pool.
The role of BCAA in muscle nitrogen metabolism is thus tied to the fate of the mitochondrial glutamate produced from the transamination reaction. The mitochondrial glutamate-aspartate carrier catalyzes the electrogenic uptake of glutamate coupled with the efflux of aspartate; therefore, glutamate produced by BCATm cannot leave the mitochondria via this carrier but must exit on the glutamate-hydroxyl carrier. Unlike the glutamateaspartate carrier (C-5 and C-4 carbon skeleton exchange), exit of glutamate on the glutamate-hydroxyl carrier results in efflux of a C-5 carbon skeleton (␣-ketoglutarate) from the mitochondria and a net loss of citric acid cycle intermediates. The other exchange carriers, such as ␣-ketoglutarate-malate and citrate do not deplete the citric acid cycle intermediates as efflux and uptake are balanced. Loss of ␣-ketoglutarate will not occur if the glutamate produced by the BCATm reaction undergoes oxidative deamination via glutamate dehydrogenase because this step would regenerate ␣-ketoglutarate and produce free ammonia and ␤-nicotinamide adenine dinucleotide (reduced form) inside the mitochondria. Although the concentration of glutamate dehydrogenase in human muscle is controversial (47) (48) (49) , a BCATm-glutamate dehydrogenase couple could provide ammonia for glutamine synthesis without compromising citric acid cycle activity. Operation of the combined pathways would provide both net glutamate and ammonia for glutamine synthesis, if loss of C-5 carbon from the citric acid cycle was balanced via anaplerotic reactions (amino acid oxidation). Clearly, assessment of the relative importance of these 2 pathways requires more information on the relative activities of the enzymes and carrier systems in vitro and complete flux data in vivo. We are currently investigating these areas.
